Jeffrey Graybill
Vice President, CMC Commercial Strategy, Immatics
Jeffrey Graybill is listed as Vice President, CMC Commercial Strategy, Immatics. Jeffrey is scheduled to speak at Advanced Therapies Week 2027 on 20 January 2027.
Compiled from published conference agendas; not yet confirmed by Jeffrey. Is this you? Claim this profile.
About
Jeffrey Graybill is Vice President, CMC Commercial Strategy at Immatics, where he leads Operations and Manufacturing readiness activities supporting the planned launch of anzu-cel, Immatics' Phase 3 TCR-T therapy for melanoma. Prior to joining Immatics, Jeff held cross-functional CMC Operations leadership roles at Bristol Myers Squibb, supporting the global launch and lifecycle management of Breyanzi®, the company's first CAR-T cell therapy. Earlier in his career, he held Supply Chain and Operations positions at Amgen, with responsibilities spanning clinical supply chain, project management, and medical device development. Jeff holds a Master of Bioscience degree from Keck Graduate Institute and a Bachelor of Science in Bioengineering from Louisiana State University.
Upcoming
Advanced Therapies Week 2027 19 January 2027 – 21 January 2027
- Session 5: Stepping back and reviewing the advanced therapy sector’s approach to automation Speaker · 20 January 2027
- Spotlight: LIfe-cycle management of CGT manufacturing process - managing the evolution of a CGT manufacturing process to build in robustness, reduce risk, and manage COGS Speaker · 20 January 2027
Spoke alongside
People who have shared a session with Jeffrey at events on B2DB.
- Dena Flamm Business Development Manager · OPTIMA packaging group GmbH 1 shared session
- Greg Russotti Chief Technology & Manufacturing Officer · Century Therapeutics 1 shared session
- Sarah Yuan Chief Technology Officer · Cabaletta Bio 1 shared session
- Vilma Methner Senior Market Development Manager - ATMP · OPTIMA packaging group GmbH 1 shared session
- Xavier de Mollerat du Jeu Global Head of Automation · Legend Biotech 1 shared session